Claims for Patent: 9,320,710

Summary for Patent: 9,320,710

Title:	Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
Abstract:	Compositions, systems and methods for administration of small volume sufentanil drug dosage forms to the sublingual mucosa of a subject for treatment of pain using a device are disclosed.
Inventor(s):	Palmer; Pamela (San Francisco, CA), Schreck; Thomas (Portola Valley, CA), Tzannis; Stelios (Petaluma, CA), Hamel; Larry (Pacific Grove, CA), Poutiatine; Andrew I. (Mill Valley, CA)
Assignee:	AcelRX Pharmaceuticals, Inc. (Redwood City, CA)
Application Number:	14/517,260
Patent Claims:	1. A method of treating pain in a subject, comprising administering a bioadhesive dosage form to the oral mucosa of a subject, wherein said bioadhesive dosage form comprises: from about 2 micrograms to about 200 micrograms sufentanil, wherein said dosage form is bioadhesive and has a volume of less than 30 microliters or a mass of less than 30 mg. 2. The method according to claim 1, wherein the dosage form has a volume of less than 10 microliters or a mass of less than 10 mg. 3. The method according to claim 1, wherein after administration of the dosage form to the subject, at least 50% of the drug delivery of sufentanil occurs via the oral transmucosal route. 4. The method according to claim 3, wherein after administration of the dosage form to the subject, at least 55% of the drug delivery of sufentanil occurs via the oral transmucosal route. 5. The method according to claim 3, wherein after administration of the dosage form to the subject, at least 60% of the drug delivery of sufentanil occurs via the oral transmucosal route. 6. The method according to claim 1, wherein after administration of the dosage form to the subject, the dosage form provides a Tmax of from about 19.8 minutes to about 60 minutes. 7. The method according to claim 1, wherein after administration of the dosage form to the subject, the dosage form provides a mean Tmax of from 0.68 to 0.89 hours. 8. The method according to claim 1, wherein after administration of the dosage form to the subject results in a dose-normalized C.sub.max of about 2.72+/-0.84 pg/mL per mcg dosed. 9. The method according to claim 1, wherein the bioadhesive dosage form adheres to the oral mucosa of said subject during the period of drug delivery. 10. The method according to claim 9, wherein the bioadhesive dosage form adheres to the sublingual membrane of said subject during the period of drug delivery. 11. The method according to claim 9, wherein the bioadhesive dosage form adheres to the buccal membrane of said subject during the period of drug delivery. 12. The method according to claim 1, wherein after administration of the dosage form to the subject, the dosage form provides a Tmax with a coefficient of variation less than 40%. 13. The method according to claim 1, wherein a single oral transmucosal administration of the dosage form to the subject results in a bioavailability of greater than 65%. 14. The method according to claim 1, wherein a single oral transmucosal administration of the dosage form to the subject results in a bioavailability of greater than 75%. 15. The method according to claim 1, wherein a single oral transmucosal administration of the dosage form to the subject results in a bioavailability of greater than 80%. 16. The method according to claim 1, wherein sufentanil is sufentanil citrate. 17. The method according to claim 1, wherein said bioadhesive dosage form is administered using a drug delivery device.